Adage, Atchinson, Gross report zero INZY ownership in 13G/A
Rhea-AI Filing Summary
Adage Capital Management, L.P., together with principals Robert Atchinson and Phillip Gross, filed an Amendment to Schedule 13G for Inozyme Pharma, Inc. (INZY). The filing reports 0.00 shares beneficially owned and 0% of the class, with sole and shared voting and dispositive power all shown as 0. The issuer's principal executive office is listed at 321 Summer Street, Suite 400, Boston, MA, and the reporting persons' business address is 200 Clarendon Street, 52nd Floor, Boston, MA. Signatures dated 08/12/2025 certify the information and state the securities were not acquired to influence control.
Positive
- None.
Negative
- None.
Insights
TL;DR: Adage's 13G/A shows no ownership of INZY, so there is no material ownership stake or voting influence reported.
The filing explicitly reports 0.00 shares and 0% beneficial ownership for Adage Capital Management, L.P., and the named individuals. That means the reporting persons do not hold a reported economic or voting position in Inozyme Pharma under this filing. For investors, this disclosure is informational and does not reflect an active stake or change in ownership that would affect company control or capital structure.
TL;DR: Formal Schedule 13G/A filing with certifications; no indication of control intent or group ownership.
The statement includes the standard certification that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control. Item responses show ownership of 5 percent or less and Items 6–9 are marked Not Applicable. Signatures from Adage and the two individuals dated 08/12/2025 complete the filing. Procedurally sound but not material to governance given the reported 0% ownership.
FAQ
What does the Schedule 13G/A filed for INZY state about ownership?
Who filed the Schedule 13G/A for Inozyme Pharma (INZY)?
What are the relevant dates in the INZY 13G/A filing?
What addresses are listed in the INZY Schedule 13G/A?
Does the filing indicate any intent to influence control of Inozyme (INZY)?
AI-generated analysis. How Rhea-AI works. Not financial advice.